Background: In dual antiplatelet therapy (DAPT), low-dose acetylsalicylic acid is combined with a P2Y12 inhibitor. However, combining antithrombotic agents increases the risk of bleeding. Guidelines on DAPT recommend using this combination for a limited period of between three weeks and 30 months. This implies the risk of DAPT being erroneously continued after the intended stop date.Objective: The primary objective of this study is to assess the proportion of hospitalized patients treated with DAPT whose treatment deviated erroneously and unintentionally from the guidelines. We also assessed risk factors and the effect of a pharmacist intervention.Methods: All patients admitted to the Spaarne Gasthuis (Haarlem/ Hoofddorp, the Netherlands) w...
OBJECTIVES Despite guideline recommendations, previous reports, coming mainly from outside Europe...
ABSTRACTBackground: Recent approval of the new oral anticoagulants dabigatran and rivaroxaban has le...
Purpose: Patients on dual and triple antithrombotic therapy present the therapeutic dilemma of mitig...
Background: In dual antiplatelet therapy (DAPT), low-dose acetylsalicylic acid is combined with a P2...
Background: In dual antiplatelet therapy (DAPT), low-dose acetylsalicylic acid is combined with a P2...
Background: In dual antiplatelet therapy (DAPT), low-dose acetylsalicylic acid is combined with a P2...
Purpose Treatment schedules for antithrombotic therapy are complex, and there is a risk of inappropr...
Temporary interruption of dual antiplatelet therapy (DAPT) is not infrequently required in patients ...
Dual antiplatelet therapy (DAPT) is integral to the management of coronary artery disease (CAD) but ...
Introduction a € Real world' bleeding in patients exposed to different regimens of dual antiplatelet...
OBJECTIVES: This study aimed to evaluate the adherence to protocols for the use of reversal agents i...
Dual antiplatelet therapy (DAPT) has been the cornerstone of antithrombotic management for patients ...
Introduction ‘Real world’ bleeding in patients exposed to different regimens of dual antiplatelet th...
Temporary interruption of dual antiplatelet therapy (DAPT) is not infrequently required in patients ...
Current guidelines for patients with acute coronary syndrome (ACS) recommend dual antiplatelet thera...
OBJECTIVES Despite guideline recommendations, previous reports, coming mainly from outside Europe...
ABSTRACTBackground: Recent approval of the new oral anticoagulants dabigatran and rivaroxaban has le...
Purpose: Patients on dual and triple antithrombotic therapy present the therapeutic dilemma of mitig...
Background: In dual antiplatelet therapy (DAPT), low-dose acetylsalicylic acid is combined with a P2...
Background: In dual antiplatelet therapy (DAPT), low-dose acetylsalicylic acid is combined with a P2...
Background: In dual antiplatelet therapy (DAPT), low-dose acetylsalicylic acid is combined with a P2...
Purpose Treatment schedules for antithrombotic therapy are complex, and there is a risk of inappropr...
Temporary interruption of dual antiplatelet therapy (DAPT) is not infrequently required in patients ...
Dual antiplatelet therapy (DAPT) is integral to the management of coronary artery disease (CAD) but ...
Introduction a € Real world' bleeding in patients exposed to different regimens of dual antiplatelet...
OBJECTIVES: This study aimed to evaluate the adherence to protocols for the use of reversal agents i...
Dual antiplatelet therapy (DAPT) has been the cornerstone of antithrombotic management for patients ...
Introduction ‘Real world’ bleeding in patients exposed to different regimens of dual antiplatelet th...
Temporary interruption of dual antiplatelet therapy (DAPT) is not infrequently required in patients ...
Current guidelines for patients with acute coronary syndrome (ACS) recommend dual antiplatelet thera...
OBJECTIVES Despite guideline recommendations, previous reports, coming mainly from outside Europe...
ABSTRACTBackground: Recent approval of the new oral anticoagulants dabigatran and rivaroxaban has le...
Purpose: Patients on dual and triple antithrombotic therapy present the therapeutic dilemma of mitig...